Idarucizumab administration in a patient with incarcerated bowel hernia
Cor et Vasa, vol.6, no.6, pp.623-624, 2019 (Scopus)
- Publication Type: Article / Article
- Volume: 6 Issue: 6
- Publication Date: 2019
- Doi Number: 10.1016/j.crvasa.2018.09.008
- Journal Name: Cor et Vasa
- Journal Indexes: Scopus
- Page Numbers: pp.623-624
- Keywords: Anticoagulants, Antidotes, Atrial fibrillation
- Open Archive Collection: AVESIS Open Access Collection
- Akdeniz University Affiliated: Yes
Abstract
Atrial fibrillation is the most common rhythm disorder worldwide. Oral anticoagulants are used in the treatment of atrial fibrillation. Non-Vitamin K oral anticoagulants have been used more often because of the fact that they are more effective and safer than conventional warfarin therapy. The absence of antidote in the majority of new generation oral anticoagulants leads to some difficulties in clinical usage. Idarucizumab, a recently introduced drug, is used in reversing the dabigatran effect in cases of lethal bleeding or acute surgery and invasive procedures. However, little data are available on the efficacy and safety of idarucizumab in geriatric patients. Here, we present a case of the successful administration of idarucizumab in a geriatric patient with incarcerated bowel hernia.